Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Common Equity (2016 - 2025)

Marimed (MRMD) has disclosed Common Equity for 15 consecutive years, with $50.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 14.58% to $50.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Dec 2025, down 14.58% year-over-year, with the annual reading at $50.0 million for FY2025, 14.58% down from the prior year.
  • Common Equity for Q4 2025 was $50.0 million at Marimed, down from $54.3 million in the prior quarter.
  • The five-year high for Common Equity was $80.9 million in Q2 2023, with the low at $14.7 million in Q1 2021.
  • Average Common Equity over 5 years is $54.3 million, with a median of $57.1 million recorded in 2022.
  • The sharpest move saw Common Equity soared 41994.93% in 2021, then dropped 19.93% in 2025.
  • Over 5 years, Common Equity stood at $36.3 million in 2021, then surged by 57.88% to $57.3 million in 2022, then rose by 20.2% to $68.9 million in 2023, then decreased by 15.01% to $58.5 million in 2024, then fell by 14.58% to $50.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $50.0 million, $54.3 million, and $56.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.